INCRUSE ELLIPTA 55 mcg INHALATION POWDER, SINGLE-DOSE

2. What you need to know before you start using Incruse Ellipta

Do not use Incruse Ellipta

• if you are allergic to umeclidinium or any of the other ingredients of this medicine (listed in section 6).

If you think the above applies to you, do not usethis medicine until you have consulted your doctor.

Warnings and precautions

Consult your doctor before starting to use Incruse Ellipta:

• if you have asthma(do not use Incruse Ellipta to treat asthma)
• if you have heart problems
• if you have an eye problem called narrow-angle glaucoma
• if you have enlarged prostate, difficulty urinating, or a blockage in the bladder
• if you have severe liver problems.

Consult your doctorif you think any of the above conditions apply to you.

Immediate breathing difficulties

If you experience chest tightness, coughing, wheezing, or difficulty breathing immediately after using your Incruse Ellipta inhaler:

stop using this medicine and seek medical attention immediately, as you may have a serious condition called paradoxical bronchospasm.

Eye problems during treatment with Incruse Ellipta

If you experience eye pain or discomfort, blurred vision for a time, halos, or colored images associated with redness of the eyes during treatment with Incruse Ellipta:

stop using this medicine and seek medical help immediately, as these signs may be due to an acute attack of narrow-angle glaucoma.

Children and adolescents

Do not give this medicine to children or adolescents under 18 years.

Other medicines and Incruse Ellipta

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. If you are not sure what your medicine contains, consult your doctor or pharmacist.

In particular, tell your doctor or pharmacist if you are taking other long-acting medicines to treat similar respiratory problems to this medicine, such as tiotropium. Do not use Incruse Ellipta with these medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctorbefore using this medicine. If you are pregnant, do not use this medicine unless your doctor tells you to.

It is not known if the components of Incruse Ellipta can be excreted in breast milk. If you are breastfeeding, consult your doctorbefore using Incruse Ellipta.

If you are breastfeeding, do not use this medicine unless your doctor tells you to.

Driving and using machines

It is unlikely that this medicine will affect your ability to drive or use machines.

Incruse Ellipta contains lactose

If your doctor has told you that you have an intolerance to some sugars, consult them before using this medicine.

3. How to use Incruse Ellipta

Follow the instructions for administration of this medicine exactly as your doctor has told you. If you are not sure, consult your doctor or pharmacist again.

The recommended doseis one inhalation every day, at the same time each day. You only need one inhalation per day, as the effect of this medicine lasts for 24 hours.

Do not use more doses than your doctor has told you to.

Use Incruse Elliptaregularly

It is very important that you use Incruse Ellipta every day, as your doctor has told you. This will help you not to have symptoms throughout the day and night.

Do notuse this medicine to relieve a sudden attack of shortness of breath or wheezing. If you have this type of attack, you should use a fast-acting "rescue" inhaler (such as salbutamol).

How to use the inhaler

To get the full information, read the "Step-by-step instructions for use" at the end of this package leaflet.

The administration of Incruse Ellipta is by inhalation. To use Incruse Ellipta, breathe it into your lungs through your mouth using the Ellipta inhaler.

If your symptoms do not improve

If your COPD symptoms (shortness of breath, wheezing, coughing) do not improve or worsen, or if you are using your fast-acting "rescue" inhaler more often than usual:

contact your doctor as soon as possible.

If you use more Incruse Ellipta than you should

If you accidentally use too much medicine, contact your doctor or pharmacist immediately, as you may need medical attention. If possible, show them the inhaler, packaging, or package leaflet. You may notice that your heart beats faster than normal, you have vision changes, or your mouth is dry.

If you forget to use Incruse Ellipta

Do not inhale a double dose to make up for forgotten doses.Inhale the next dose at the usual time.

If you have wheezing or shortness of breath, use your fast-acting "rescue" inhaler (such as salbutamol) and seek medical advice.

If you stop using Incruse Ellipta

Use this medicine for as long as your doctor recommends. It will only be effective for as long as you use it. Do not stop using it until your doctor tells you to, even if you feel better, as your symptoms may worsen.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions

If after using Incruse Ellipta you have any of the following symptoms, stop using thismedicine and tell your doctor immediately:

Uncommon(may affect up to 1 in 100people):

• itching
• rash (hives) or redness.

Rare(may affect up to 1 in 1,000people):

• wheezing (a whistling sound when breathing), coughing, or difficulty breathing
• a sudden feeling of weakness or dizziness (which may cause fainting or loss of consciousness)

Other side effects:

Common(may affect up to 1 in 10people):

• fast heart rate
• pain when urinating and increased frequency (may be signs of a urinary tract infection)
• common cold
• nose and throat infection
• coughing
• feeling of pressure or pain in the cheeks and forehead (may be symptoms of sinusitis, an inflammation of the nasal passages)
• headache
• constipation
• mouth and throat pain.

Uncommon(may affect up to 1 in 100people):

• irregular heartbeat
• sore throat
• dry mouth
• change in taste
• hoarseness.

Rare(may affect up to 1 in 1,000people):

• eye pain.

Frequency not known(frequency cannot be estimated from the available data):

• decreased vision or eye pain due to increased eye pressure (possible signs of glaucoma)
• blurred vision
• increased eye pressure
• difficulty and pain when urinating, this may be a sign of bladder obstruction or urinary retention
• dizziness.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this package leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Incruse Ellipta

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the packaging, tray, and inhaler, after EXP. The expiry date is the last day of the month stated.

Keep the inhaler in the sealed tray to protect it from moisture and only remove it immediately before the first use. Once the tray is opened, the inhaler can be used for a period of 6 weeks, counting from the date of opening of the tray. Write the date when the inhaler should be discarded on the space provided on the inhaler label. The date should be noted as soon as the inhaler is removed from the tray.

Do not store above 30 °C.

If you store it in the refrigerator, let the inhaler return to room temperature at least one hour before use.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container contents and additional information

Incruse Ellipta composition

The active ingredient is umeclidinium (as bromide).

Each inhalation provides a delivered dose (dose that comes out of the mouthpiece) of 55 micrograms of umeclidinium (equivalent to 65 micrograms of umeclidinium bromide).

The other ingredients are lactose monohydrate (see section “Incruse Ellipta contains lactose” in section 2) and magnesium stearate.

Appearance of the product and container contents

Incruse Ellipta is a powder for inhalation (single-dose).

The Ellipta inhaler consists of a gray plastic body, a light green mouthpiece cover, and a dose counter. It is packaged in a laminated aluminum tray with a foldable aluminum foil. The tray contains a bag with a desiccant to reduce moisture in the container.

The active ingredient is presented as a white powder in a blister inside the inhaler. Incruse Ellipta is available in packs of one inhaler containing 7 or 30 doses and in multipacks of 90 doses (3 inhalers of 30 doses). Only some pack sizes may be marketed.

Marketing authorization holder:

GlaxoSmithKline Trading Services Limited

12 Riverwalk

Citywest Business Campus

Dublin 24

Ireland

D24 YK11

Manufacturer:

Glaxo Wellcome Production

Zone Industrielle No.2

23 Rue Lavoisier

27000 Evreux

France

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Date of last revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.

Step-by-step instructions for use

What is the Ellipta inhaler?

The first time you use Incruse Ellipta, you do not need to check that the inhaler is working correctly, as it contains pre-measured doses and is ready to use directly.

Your Incruse Ellipta inhaler pack contains:

The inhaler is packaged in a tray. Do not open the tray until you are ready to start using your new inhaler. When you are ready to use the inhaler, remove the lid to open the tray. The tray contains a bag with a desiccantto reduce moisture. Discard the desiccant bag, do notopen it, ingest it, or inhale it.

When you remove the inhaler from its tray, it will be in the “closed” position. Do not open the inhaler until you are ready to inhale a dose of medicine.When the tray is opened, the “Discard by” date should be noted on the space provided on the inhaler label. The “Discard by” date is 6 weeks from the date of opening the tray. After this date, the inhaler should not be used. The tray can be discarded once it is opened.

If stored in the refrigerator, let the inhaler reach room temperature for at least one hour before use.

The step-by-step instructions for using the Ellipta inhaler provided below can be used for both the 30-dose inhaler (30 days of treatment) and the 7-dose inhaler (7 days of treatment).

1. Read this information before starting

If the inhaler cap is opened and closed without inhaling the medicine, the dose will be lost.The lost dose will be retained safely inside the inhaler, but it will not be available for inhalation.

It is not possible to accidentally administer an additional dose or a double dose through an inhalation.

1. Prepare a dose

Wait to open the inhaler cap until you are ready to inhale a dose.

Do not shake the inhaler.

• Slide the cap down until you hear a ‘click’.

Now, the medicine is ready to be inhaled.

As confirmation, the dose counter decreases by 1unit.

• If the dose counter does not decrease when you hear the ‘click’, the inhaler will not release the dose of medicine.

Take it to the pharmacist and ask for help.

1. Inhale your medicine

• While holding the inhaler away from your mouth, breathe out as much as you can.

Do notbreathe out into the inhaler.

• Place the mouthpiece between your lips, and close them firmly around the mouthpiece.

Do notblock the ventilation slots with your fingers.

• Take a long, steady, and deep breath in. Hold your breath for as long as you can (at least 3-4 seconds).
• Remove the inhaler from your mouth.
• Breathe out slowly and gently.

You may not be able to taste or feel the medicine, even when using the inhaler correctly.

Beforeclosing the cap, the inhaler mouthpiece can be cleaned using a dry cloth.

1. Close the inhaler

• Slide the cap up, to the top, to cover the mouthpiece.